Sesen Bio Inc

Sesen Bio — Corporate Update (March 2020)

62 slides from Sesen Bio's corporate update, Mar 16, 2020

  1. Slide 1: March 2020 Business Update

    March 2020 Business Update March 16, 2020 NASDAQ: SESN For investor purposes only

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical devel

  3. Slide 3: March 2020 Business Update

    MARCH 2020 BUSINESS UPDATE • Significant unmet medical need for patients, caregivers and payers • Highly differentiated mechanism of action and clinical profile • New market research supports large commercial opportunity • Clear regulatory path forward ForFFoor iininvestornveeststoor ppurposesuurrpo

  4. Slide 4: Bladder cancer patient journey

    BLOOD IN URINE See PCP; therapeutic trial of antibiotics prescribed IN BLADDER CANCER, THE Still see blood in urine See UROLOGIST GUIDES THE PATIENT blood in urine; try different antibiotic Confusion and concern on problem JOURNEY Begin tests REFERRED TO Shock and UROLOGIST st CT Scan emotional Prep

  5. Slide 5: Highly Differentiated Mechanism of Action

    Highly Differentiated Mechanism of Action Mechanism 1: Mechanism 2: Kills cell directly Activates immune system Vicinium selectively targets EpCAM on T cells recognize neoantigen cancer cells while and kill cancer cells generally leaving healthy cells alone Vicinium causes immunogenic cell death by

  6. Slide 6: Highly Differentiated Clinical Profile

    Highly Differentiated Clinical Profile Efficacy Data Safety Data 3 month response data Intravesical administration • CIS: 40% complete response rate • Bladder wall serves protective function • Papillary: 71% recurrence-free rate • Preference of FDA* and most Urologists Durability of response Clinica

  7. Slide 7: 1Q 2020 Intent-to-Prescribe Market Research Results

    1Q 2020 Intent-to-Prescribe Market Research Results We conducted 30-minute interviews with 34 high- prescribing Urologists to assess their views of the Vicinium profile vs. the Keytruda profile based on available clinical information For investor purposes only 7

  8. Slide 8: Market Research Input: Profile of Emerging Treatments for NMIBC

    Market Research Input Profile of Emerging Treatments for NMIBC Keytruda Profile Vicinium Profile Binds to the PD-1 receptor, blocking both PD-L1 and Selectively targets and kills bladder cancer cells while Mechanism of Action PD-L2 from interacting with PD-1 to help restore T cell- sparing healthy c

  9. Slide 9: Market Research Input: Clinical Data from Emerging Treatments

    Market Research Input Clinical Data from Emerging Treatments for NMIBC Keytruda Profile Vicinium Profile Efficacy N=102 N=89 Complete Response Rate • At 3 Months 41% (CI: 32-51) 40% (CI: 30-51) • At 12 Months 20% 17% • At 18 Months 13% 11% 76% of patients were cystectomy-free Time to Cystectomy No d

  10. Slide 10: Urologists Prefer Vicinium Profile: Key Attributes

    Market Research Results High Prescribing Urologists Prefer Vicinium Profile: Key Attributes Extremely 10.0 9.0 8.6 8.2 8.2 8.0 7.0 6.2 6.0 5.8 5.4 5.2 5.0 4.0 3.4 Average Rating Average 3.0 2.0 1.0 Not at all 0.0 Efficacy Safety Ease of integration Interest in use of product Vicinium Profile Keytrud

  11. Slide 11: Urologists Prefer Vicinium Profile: Intent to Prescribe

    Market Research Results High Prescribing Urologists Prefer Vicinium Profile: Intent to Prescribe Urologists generally choose branded Urologists who prefer branded agents state they agents over radical cystectomy would choose the Vicinium profile over the 90% 90% 83% Keytruda profile 80% 80% 80% 70%

  12. Slide 12: Reasons Urologists Prefer Vicinium Profile

    Market Research Results Reasons Urologists Prefer Vicinium Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perceive favora

  13. Slide 13: Highly Concentrated Prescriber Base Allows Efficient Commercial Model

    Highly Concentrated Prescriber Base Allows for Efficient Commercial Model aRI8URORJ\SUDFWLFHVKDYH•8URORJLVWV1 BCG Prescribers2 100% 90% 80% 70% 60% ~1,500 Urologists treat 75% of patients % of % Patients 50% 40% 30% 20% 10% 0% 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 2,200 2,4

  14. Slide 14: Pricing and Reimbursement

    Pricing and Reimbursement US Benchmarks Price Reference Payer Management Responses (Annual Cost) to Pricing2 100% $200K Anticipated Keytruda1 competitive pricing $150K 50% Proportion of Payers Proportion of $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA to Label Key: PA to Trial Ris

  15. Slide 15: Significant Progress in 2019

    Significant Progress in 2019 4 Pivotal Face-to-Face Meetings Lead to BLA Submission of Clinical/Nonclinical Data 9 May 2019: FDA Accepts CMC Analytical Comparability Plan • No additional clinical trials deemed necessary at this time, subject to final review of comparability data in the BLA 9 June 20

  16. Slide 16: Regulatory Path Forward

    Regulatory Path Forward Key CMC activities in 2020 are designed to demonstrate analytical comparability between commercial and clinical supply for the finalization of the BLA submission 2019 2020 2021 4Q 1Q 2Q 3Q 4Q 1Q 2Q Initiated BLA Finalize BLA Potential approval submission ssubmissionubm CMC Pr

  17. Slide 17: Financial Overview as of December 31, 2019

    Financial Overview as of December 31, 2019 Cash position • Ending cash and cash equivalents of $48.1M • Sufficient cash to fund key strategic priorities into 2021 Capital structure • 106.8 M shares of common stock outstanding – No preferred stock – 136 M fully diluted1 • No Debt For investor purpose

  18. Slide 18: 2019 Key Highlights

    2019 KEY HIGHLIGHTS • Significant unmet medical need for patients, caregivers and payers • Highly differentiated mechanism of action and clinical profile • New market research supports large commercial opportunity • Clear regulatory path forward ForFFoor iininvestornveeststoor ppurposesuurrpoposeses

  19. Slide 19: Talented and Experienced Leadership Team

    Talented and Experienced Leadership Team Prepared for Commercial Launch Senior Management Board of Directors Omar Rifi Thomas Cannell, DVM Jay Duker, M.D. Vice President, Business Development President, CEO and Director Chair of the Board of Directors and Alliance Management Carrie L. Bourdow Monica

  20. Slide 20: Appendix - Table of Contents

    Appendix - Table of Contents Section Slide number Patient Journey 21-22 Unmet Medical Need 23-26 Dual Mechanism of Action 27-29 Regulatory 30-34 Clinical Data 35-49 Commercial Opportunity 50-55 Manufacturing & Supply Chain 56-60 Intellectual Property 61-62 For investor purposes only 20

  21. Slide 21: Appendix: Patient Journey

    Appendix Patient Journey For investor purposes only 21

  22. Slide 22: Patient experience in bladder cancer is among the poorest

    Patient surveys have shown that the experience of those with bladder cancer is one of the poorest1 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Cancers2 90 86 80 75 72 68 70 65 60 50 47 40 30 % of Patients Who Had Experience % of Patients 20 10 0 M

  23. Slide 23: Appendix: Unmet Medical Need

    Appendix Unmet Medical Need For investor purposes only 23

  24. Slide 24: Significant Unmet Medical Need in NMIBC

    Significant Unmet Medical Need in NMIBC ~440,000 Bladder cancer is the 6th most prevalent cancer in the US, of which 75%-85% is NMIBC2,3 new cases each year globally1 Bladder cancer is the most expensive cancer to treat in the US with projected costs of ~$6B by 20204 One of the worst patient experie

  25. Slide 25: Vicinium is cystectomy-sparing by delaying or avoiding cystectomy

    Our Phase III data suggests Vicinium is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery ƒ Self-controlled storage organ in ƒ Often a 10 hour or longer surgery the body ƒ In women, removal of t

  26. Slide 26: Latest global BCG shortage expected to last through 2020

    Latest global BCG shortage expected to last through 2020 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints of BCG Tice strain

  27. Slide 27: Appendix: Dual Mechanism of Action

    Appendix Dual Mechanism of Action For investor purposes only 27

  28. Slide 28: Vicinium Highly Differentiated with Dual Mechanism of Action

    Vicinium is Highly Differentiated and has a Dual Mechanism of Action • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets cancer cells while generally sparing healthy cells • Inhibits pr

  29. Slide 29: High somatic mutation rate in bladder cancer

    The high somatic mutation rate in bladder cancer may lead to a better response to agents such as Vicinium that may stimulate T cell-mediated immune activation driven by neoantigens For investor purposes only Adapted from Zahir et al. Nature Medicine, 2017 29

  30. Slide 30: Appendix: Regulatory

    Appendix Regulatory For investor purposes only 30

  31. Slide 31: Program aligned with FDA guidance

    Our long-term relationship with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicinium Clinical Program • Conduct nonclinical studies to assess toxicity in animal models 9 • Conduct nonclinical studies to demonstrate anti-tum

  32. Slide 32: Strong benefit-risk profile in Phase III Trial

    Vicinium demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit Risk : Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp

  33. Slide 33: Initiation of Vicinium BLA submission under Rolling Review

    Initiation of Vicinium BLA submission under Rolling Review on December 6, 2019 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submission 82% As part of a compr

  34. Slide 34: Key Elements of BLA Submission for Vicinium

    Key Elements of BLA Submission for Vicinium We initiated our BLA submission under Rolling Review on December 6th and believe this significantly de-risks the regulatory path to approval Module 1 Module 2 Module 3 Module 4 Module 5 ¾ General corporate ¾ Introduction to summary ¾ Drug substance ¾ 24 No

  35. Slide 35: Appendix: Clinical Data

    Appendix Clinical Data For investor purposes only 35

  36. Slide 36: Phase III Trial: Patient Demographics

    Phase III Trial: Patient Demographics COHORT 1COHORT 2COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months PRQWKVEXW”PRQWKVRI CIS) that were refractory of adequate BCG adequate BCG or recurred within 6 months of adequate B

  37. Slide 37: Compelling Clinical Data Set

    Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95% CI rules out clinically unmeaningful CRR disease, or disease progres

  38. Slide 38: Phase III Trial: Evaluable Patient Data Tables by Cohort

    Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 17%

  39. Slide 39: Complete and Partial Response

    Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response 3-Month3-Month Responsep 40% of patients had a complete response StartStart ofof TreatmentTreatment with 43% of patients had a partial response ViciniumVicinium 17% of ppatientsatients h

  40. Slide 40: Duration of Response: 52% disease-free at 12 months

    Duration of Response: 52% of CIS patients who had a complete response at 3 months remained disease-free for a total of 12 months after starting treatment Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40 % of Patients wit

  41. Slide 41: Duration of Response: Longer response, higher probability of remaining cancer-free

    Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free Probability of Maintaining Complete Response (CR) for at Each time point a CR is confirmed, the probability of Least One Additional Year* maintaining a CR increases 11/14 responders at

  42. Slide 42: Duration of Response: More efficacious with less BCG

    Duration of Response: Vicinium is generally more efficacious in CIS patients treated with less BCG The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations •%&*LQVWLOODWLRQV 80 X Censored 60 Median 40 20 % of Patients with Complete Response 0 3

  43. Slide 43: Time to Disease Recurrence

    Time to Disease Recurrence: For high-risk papillary patients who were treated with Vicinium, 50% are disease-free at 1 year Median time to recurrence is 402 days per Kaplan-Meier estimate (13.2 months) 100 Legend: 80 KM Estimate X Censored 95% CI 60 50% 40 37% % of Patients Recurrence-Free 20 0 0 3

  44. Slide 44: Recurrence-free Rate in high-risk papillary patients

    Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-months n=38 4

  45. Slide 45: Time to Cystectomy: 76% cystectomy-free at 3 years

    Time to Cystectomy: 76% of patients remain cystectomy-free for at least 3 years No patient on treatment progressed to metastatic disease 100 80 60 Median 40 Legend: KM Estimate 20 X Censored % of Patients % of Patients Cystectomy-Free 95% CI 0 0 3 6 9 12 15 18 21 24 27 30 33 Time on treatment (month

  46. Slide 46: Time to Cystectomy: Responders vs non-responders

    Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment The average responder remains cystectomy-free for 1,035 days vs 631 days for non-responders 100 Statistically significant difference for 80 responders vs. non-responders: p = < 0.001

  47. Slide 47: Safety and Tolerability: Phase II and III consistent

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Treatment-related serious adverse Patient

  48. Slide 48: Safety and Tolerability: No age-related increase in adverse events

    Safety and Tolerability: No age-related increase in adverse events in our Phase III trial The average patient in the VISTA trial was ~74 years old Adverse Events 10 9.0 Treatment-related Adverse Events 7.9 8 7.5 6 4 3.0 Mean AEs/patient Mean 2.1 2 1.6 0 54-69 70-79 80+ (n=40) (n=57) (n=36) Age (year

  49. Slide 49: Pipeline of Targeted Therapies

    Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicinium in combination with checkpoint inhibitors. Vicinium in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 study run by the National Cancer Institute. PRODUCT CAND

  50. Slide 50: Appendix: Commercial Opportunity

    Appendix Commercial Opportunity For investor purposes only 50

  51. Slide 51: Virtuous Cycle: Physicians, Patients, Payers

    Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicinium before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo

  52. Slide 52: Large Global Commercial Opportunity

    Large Global Commercial Opportunity Substantial US opportunity and OUS potential of 2-3 times the US • We have CMO partners capable of reliably meeting that demand Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after

  53. Slide 53: Vicinium Potential to Provide Continuity of Care for NMIBC

    Vicinium has the Potential to Provide Continuity of Care for Patients with NMIBC Checkpoint Treatment Protocol BCG Vicinium Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X

  54. Slide 54: Addressable Market (US)

    Addressable Market (US) Annual Volume ~80K1 Patients diagnosed with bladder cancer ~75% - 85% of bladder cancer diagnoses are NMIBC2 Patients diagnosed with NMIBC ~40% - 50% of NMIBCs are high-risk3 Patients with high-risk NMIBC: Papillary: ~80%2 CIS: ~20%2 ~50% - 90% of BCG treatments fail or disea

  55. Slide 55: OUS opportunity 2-3 times larger than US

    We estimate the OUS opportunity for Vicinium is 2-3 times larger than the US Geography Est. Incidence Relative to U.S.1 Est. Price Relative to U.S.2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe 1.0 – 1.2 0.60 – 1.10 (Not including EU5) North America 0.1 – 0.3 0.55 – 0.70 (Not

  56. Slide 56: Appendix: Manufacturing & Supply Chain

    Appendix Manufacturing & Supply Chain For investor purposes only 56

  57. Slide 57: Reliable and Inexpensive Manufacturing Process

    Reliable and Inexpensive Manufacturing Process Vicinium is manufactured using a robust, industry-standard microbial expression system The manufacturing process is highly reliable, reducing the risk of supply shortages The manufacturing process is inexpensive, leading to a relatively low cost-of-good

  58. Slide 58: Reliable and Inexpensive Manufacturing Process: Workflow

    Reliable and Inexpensive Manufacturing Process 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sepharose FF 2: Ni2+ IMAC

  59. Slide 59: Experienced Partners for Global Manufacturing and Supply

    We have Experienced Partners for the Global Manufacturing and Supply of Vicinium ¾ Licensed for commercial production of 8 approved products ¾ 25+ years developing and manufacturing biologics ¾ 310+ protein-based therapeutics in development and/or manufacturing ¾ Proven track record with FDA and wor

  60. Slide 60: Vicinium Commercial Manufacturing Strategy

    Vicinium Commercial Manufacturing Strategy Clinical Supply Commercial Supply Drug Substance Sesen Fuji (CMO) Drug Product Sesen Baxter (CMO) The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing • Assesses the purity, biological activity and general characte

  61. Slide 61: Appendix: Intellectual Property

    Appendix Intellectual Property For investor purposes only 61

  62. Slide 62: Vicinium Patent Life

    Vicinium Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (April 2020 - July 2020) US: 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Me

Sesen Bio — Corporate Update (March 2020) on 6ix